Immunotherapy may let some cancer patients skip the knife
NCT ID NCT06059495
First seen Aug 18, 2026 · Last updated Aug 18, 2026
Summary
This phase II trial is testing whether the immunotherapy drug dostarlimab can eliminate the need for surgery in people with a specific type of stomach or gastroesophageal junction cancer that has a genetic marker called dMMR/MSI-H. Participants receive dostarlimab infusions, and those who achieve a complete clinical response—meaning no signs of cancer on biopsies and endoscopy—may avoid surgery and instead be monitored closely. The goal is to see if a watch-and-wait approach can safely replace tumor removal in these patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- dostarlimab (Jemperli), an immunotherapy drug given by infusion
- What this could lead to
- If successful, this could show that some patients with these cancers can avoid surgery entirely, relying on immunotherapy alone to achieve a complete response.
- What could go wrong
- This is an early-phase trial with a small number of patients. Not everyone will respond, and some may still need surgery or experience side effects from the drug.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA - GEJ are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Azienda Sanitaria Universitaria friuli Centrale Presidio Ospedaliero Santa Maria della Misericordia di Udine
RECRUITINGUdine, Italy
-
Azienda USL della Romagna OSPEDALE DI RAVENNA
RECRUITINGRavenna, Italy
-
Besancon University Hospital Center
RECRUITINGBesançon, France
-
CHRU Lille
RECRUITINGLille, France
-
Centre Hospitalier De Saint Malo
NOT_YET_RECRUITINGSt-Malo, France
-
Centre Hospitalier Regional Et Universitaire De Brest
RECRUITINGBrest, France
-
Centre Hospitalier Universitaire De Bordeaux
RECRUITINGBordeaux, France
-
Centre Hospitalier Universitaire De Poitiers
RECRUITINGPoitiers, France
-
Centre Hospitalier Universitaire Reims
RECRUITINGReims, France
-
Centre Leon Berard
RECRUITINGLyon, France
-
Fondazione I.R.C.C.S. Istituto Oncologico Veneto
RECRUITINGPadova, Italy
-
Fondazione. IRCCS Istituto Nazionale dei Tumori di Milano
RECRUITINGMilan, Italy
-
Henri Mondor Hospital
RECRUITINGCréteil, France
-
Institut Mutualiste Montsouris
RECRUITINGParis, France
-
Institut Paoli Calmettes
RECRUITINGMarseille, France
-
Institut régional du Cancer de Montpellier - ICM Val d'Aurelle Oncologie Médicale
RECRUITINGMontpellier, France
-
Istituto Clinico Humanitas
RECRUITINGRozzano, Italy
-
Saint Antoine Hospital
RECRUITINGParis, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can adding immunotherapy boost a stomach cancer combo?
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can immunotherapy outperform chemo after stomach cancer surgery?
- Could a smartphone program supervised by AI boost recovery after stomach cancer surgery?
- Can stomach cancer surgery also tame diabetes?